The correct dosage and dosage of canakinumab, and how to use it?

Canakinumab(Canakinumab) is a monoclonal antibody. Canakinumab is indicated for use in adults and children ≥4 years of age with periodic fever syndromes, including hypothermia-associated periodic syndrome (CAPS), such as familial cold autoitis syndrome (FCAS) and Markle-Wells syndrome (MWS). Treatment of active Still's disease, including adult Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients ≥2 years of age.

For hypoprotein-associated periodic syndrome, the recommended dose for adults 40 kg is 150mg once every 8 weeks. The recommended dose for adults weighing 15–≤40 kg is 2 mg/kg once every 8 weeks. Tumor necrosis factor receptor-associated periodic syndrome, hyperimmunoglobulinD syndrome/mevalonate kinase deficiency, familial Mediterranean fever, 40kg adultsRecommended dose is 150 mgevery 4 weeks, if response is insufficient, increase to 300 mg every 4 weeks mg. Adults weighing ≤40kg 2mg/kg once every 4 weeks. If response is inadequate, increase to 4mg/kg every 4weeks. Still's disease For adults weighing ≥7.5kg the recommended dose is every4weeks4mg/Kilograms (up to 300mg). Before starting canakinumabtreatment, your doctor may do tests to make sure you don't have tuberculosis or other infections. Canakinumab is injected under the skin, and medical staff will inject the drug into the patient. Canakinumab is usually given every 4 to 8 weeks, depending on the condition being treated, as directed by your doctor. Tell your doctor if you have any changes in your weight. Canakinumab dosage is based on weight (especially in children and adolescents) and any changes may affect the dosage. Canakinumab can weaken the patient's immune system and the patient's blood may need to be tested frequently. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.